Anesthesia
Conditions
Brief summary
During this study, the pharmacodynamic interactions between sevoflurane and remifentanil will be studied.
Interventions
DRUGFixed sevoflurane dose 1
Dose 1 of sevoflurane
DRUGFixed sevoflurane dose 2
Dose 2 of sevoflurane
DRUGFixed sevoflurane dose 3
Dose 3 of sevoflurane
DRUGFixed sevoflurane dose 4
Dose 4 of sevoflurane
DRUGFixed sevoflurane dose 5
Dose 5 of sevoflurane
DRUGFixed sevoflurane dose 6
Dose 6 of sevoflurane
DRUGFixed remifentanil dose 1
Dose 1 of remifentanil
DRUGFixed remifentanil dose 2
Dose 2 of remifentanil
DRUGFixed remifentanil dose 3
Dose 3 of remifentanil
DRUGFixed remifentanil dose 4
Dose 4 of remifentanil
DRUGFixed remifentanil dose 5
Dose 5 of remifentanil
DRUGFixed remifentanil dose 6
Dose 6 of remifentanil
Sponsors
University Hospital, Ghent
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* American Society of Anesthesia class I and II patients * Aged 18-60 years * Scheduled for surgery under general anesthesia
Exclusion criteria
* Weight less than 70% or more than 130% of ideal body weight * Neurological disorder * Diseases involving the cardiovascular system (hypertension, coronary artery disease, prior acute myocardial infarction (AMI), any valvular and/or muscular disease involving decrease of the ejection fraction, arrhythmias, which are either symptomatic or require continuous medication/pacemaker/automatic implantable cardioverter defibrillator \[AICD\]) * Pulmonary disease including asthma, severe chronic obstructive pulmonary disease (COPD), etc. * Gastric diseases including reflux, endocrinological diseases * Recent use of psycho-active medication, including alcohol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EEG depression and arousal reactions in response to different clinically relevant stimuli | 60 to 90 minutes |
Countries
Belgium
Outcome results
None listed